New Trial (July 2026): Sirolimus-Eluting Balloon Strategy vs Routine DES
New Trial (July 2026): Sirolimus-Eluting Balloon Strategy vs Routine DES
Source: Circulation | June 15, 2026
Key Points :
• In de novo coronary lesions, a sirolimus-eluting balloon (SEB) strategy achieved similar 1-year outcomes to routine drug-eluting stents (DES).
• Bailout stenting was still required in 21% of patients treated with the balloon strategy.
• Repeat procedures were slightly more common with SEB, while safety, including thrombosis, was similar in both groups.
• Routine DES remains the standard approach, although SEB may be a reasonable option in selected patients.
Link: https://pubmed.ncbi.nlm.nih.gov/42290366/
